Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides

Dr Samuel Goldhaber


April 27, 2012

This feature requires the newest version of Flash. You can download it here.

Dr Sam Goldhaber catches up with Dr Stavros Konstantinides for a comprehensive review ofthe important trials on PE thrombolysis and a discussion of what direction future research will take.

See also:

MAPPET 1 registry of "major" PE:

Kasper W, Konstantinides S, Geibel A. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171. Available here.

Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96:882-8. Available here.

MAPPET 2 cohort study on biomarkers in PE:

Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106:1263-8. Available here.

MAPPET-3 trial:

Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-50. Available here.

Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrage with thrombolytic therapy for acute pulmonary embolism. Am J Med 2012; 125:50-56. Abstract.

Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: Saves lives but underused. Am J Med 2012; 125:465-470. Abstract.

All about Pulmonary Embolism: Assessing Risk, Managing Patients


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.